AstraZeneca (AZ) has shared positive results from a phase 3b study of its anti-inflammatory reliever rescue therapy Airsupra ...

The study found that Airsupra, its dual-action asthma rescue inhaler, led to meaningful improvements in patients with mild asthma compared to albuterol alone. AIRSUPRA is the only FDA-approved ...

In October, AstraZeneca revealed that early results from a phase 3 trial of its dual-drug asthma inhaler Airsupra were so convincing that an independent committee decided to halt the study based ...

AstraZeneca (LSE:AZN) recently announced that its AIRSUPRA therapy significantly reduced severe asthma exacerbations, generating strong interest within the medical community. Over the last month, ...

Doctors prescribe Airsupra (albuterol and budesonide) to treat asthma in adults. There’s no generic version of the medication. If you have a Medicare Part D drug plan, Medicare may cover the ...

The results from the AIRSUPRA BATURA trial add to a wide body of evidence on the value of the anti-inflammatory reliever rescue approach to not only provide immediate relief from symptoms ...

Airsupra (albuterol and budesonide) is a brand-name inhaler that doctors may prescribe to treat asthma in adults. It does not have a generic version. Medicare Part D prescription drug plans may ...

The BATURA trial, which compared as-needed AIRSUPRA against the commonly used as-needed albuterol, demonstrated a 47% reduction in the risk of a severe exacerbation for those treated with AIRSUPRA.

Positive full results from the BATURA Phase IIIb trial showed AstraZeneca’s anti-inflammatory reliever rescue therapy, AIRSUPRA (albuterol/budesonide), demonstrated statistically significant and ...